Latest News - Zoetis

Top Corporates Hub

Zoetis

ZTS | NYSE | United States
243
-43
Rank
$80.13B
Market Cap
$9.25B
+$ 0.71B
+8.31%
Revenue
$3.13B
+$ 0.7B
+28.81%
Earnings
13.8K
-0.3K
-2.13%
Employees
The Top 5 Analyst Questions From Zoetis’s Q4 Earnings Call

19.02.2026 05:38

Zoetis’ fourth quarter results were met with a muted market reaction, as headwinds in the U.S. companion animal segment and margin pressures offset revenue growth. Management pointed to lingering economic challenges among U.S. pet owners, who became more price sensitive and reduced routine veterinary visits, while persistent competition in dermatology and parasiticides weighed on growth. CEO Kristin Peck noted, "We continue to see some economic pressure on Gen Z and millennial pet owners, which

Read More

Zoetis Growth Outlook Shifts As Librela Concerns Weigh On Valuation

19.02.2026 01:16

Zoetis (NYSE:ZTS) is reporting delayed revenue growth expectations, with management now pointing to 2027 for a clearer inflection. The company is seeing slower uptake and demand challenges for Librela, its key canine arthritis pain therapy. Competitive products and reports of side-effect concerns are weighing on Librela’s traction in the market. Zoetis, a major animal health company focused on medicines, vaccines, and diagnostics for pets and livestock, is now dealing with a tougher setup...

Read More

Zoetis (ZTS) Falls Following Q3 Disappointment and Librela Demand Weakness

18.02.2026 15:05

Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile during the quarter amid concerns over elevated valuations and financing for large-scale data center investments, although the portfolio modestly outperformed the Russell 1000 benchmark […]

Read More

Bank of America Cites Zoetis Inc.’s (ZTS) Strong Q4 Performance and Fiscal 2026 Outlook

18.02.2026 09:01

Zoetis Inc. (NYSE:ZTS) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds. Zoetis Inc. (NYSE:ZTS) tops our list for being one of the cheap pharmaceutical stocks. TheFly reported on February 13 that Bank of America raised its price target for ZTS to $140 from $135 and maintained a Neutral rating on the shares. The upgraded […]

Read More

Zoetis Inc. (NYSE:ZTS) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

15.02.2026 13:15

The annual results for Zoetis Inc. ( NYSE:ZTS ) were released last week, making it a good time to revisit its...

Read More

Zoetis Faces Librela Safety Reviews While Valuation Signals Potential Upside

13.02.2026 17:12

Zoetis (NYSE:ZTS) is facing increased regulatory scrutiny of its monoclonal antibody pain drugs, with the FDA updating safety warnings for Librela. Regulators in multiple markets are reviewing adverse event reports linked to osteoarthritis pain therapies used in companion animals. At the same time, Zoetis is rolling out new pain products internationally after recent approvals in key regions. The company is also expanding its animal health diagnostics footprint through acquisitions and...

Read More

Zoetis Q4 Earnings Call Highlights

13.02.2026 12:13

Zoetis (NYSE:ZTS) executives said the company delivered organic operational growth in 2025 despite a “dynamic operating environment” marked by macroeconomic pressure on pet owners and a more competitive landscape in key companion animal categories. Management also outlined 2026 guidance calling for

Read More

B of A Securities Maintains Neutral on Zoetis, Raises Price Target to $140

13.02.2026 08:23

B of A Securities analyst Michael Ryskin maintains Zoetis (NYSE:ZTS) with a Neutral and raises the price target from $135 to $140.

Read More

ZTS Q4 Deep Dive: Product Innovation and Competitive Pressures Shape Outlook

13.02.2026 05:35

Animal health company Zoetis (NYSE:ZTS) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $2.39 billion. The company expects the full year’s revenue to be around $9.93 billion, close to analysts’ estimates. Its non-GAAP profit of $1.48 per share was 5.5% above analysts’ consensus estimates.

Read More

Jobs Report, Tech Calm Lifts Wall Street Pre-Bell; Asia, Europe Up

12.02.2026 11:21

Wall Street futures pointed moderately higher pre-bell Thursday after the Wednesday national jobs re

Read More

Zoetis (ZTS) Reports Q4: Everything You Need To Know Ahead Of Earnings

11.02.2026 03:09

Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Thursday morning. Here’s what to expect.

Read More

Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect

09.02.2026 15:22

ZTS is set up for Q4 earnings beat, fueled by strong international companion animal products sales, even as weaker U.S. demand weighs on results.

Read More

Curious about Zoetis (ZTS) Q4 Performance? Explore Wall Street Estimates for Key Metrics

09.02.2026 14:15

Evaluate the expected performance of Zoetis (ZTS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Read More

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

09.02.2026 14:00

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Read More

Should You Buy Zoetis Before Feb. 12?

09.02.2026 13:35

After walking back guidance last quarter, could this animal health company reveal surprises come earnings day?

Read More

Pelican Bay Capital Management Bets on Zoetis (ZTS) to Capitalize on Expanding Pet Care Market

06.02.2026 13:57

Pelican Bay Capital Management (PBCM), an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. PBCM Concentrated Value Strategy returned 8.5% in the quarter, compared to a 3.8% return for the Russell 1000 Value Index. The robust performance of AI-related stocks and commodities exposure drove the […]

Read More

Zoetis (ZTS) Valuation Check As 2026 Outlook Is Tempered On Softer Pet Visits And Regulatory Scrutiny

06.02.2026 01:26

Zoetis (ZTS) is back in focus after its board declared a US$0.53 per share second quarter 2026 dividend, drawing attention to how reliable cash returns fit alongside tempered 2026 expectations. See our latest analysis for Zoetis. That dividend decision lands after a choppy stretch for Zoetis, with a 7 day share price return of 4.12% and a 90 day share price return of 5.40% sitting against a 1 year total shareholder return decline of 26.16%. This suggests short term momentum is improving while...

Read More

Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?

05.02.2026 15:00

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More

Zoetis Cuts 2026 Outlook As Investors Weigh Slower Visits And Pipeline

04.02.2026 07:09

Zoetis (NYSE:ZTS) has cut its 2026 outlook, citing fewer veterinary visits as a key headwind. Leading institutional investors have flagged the slowdown in pet clinic activity as a challenge but remain supportive of the company. The update puts renewed focus on Zoetis' product portfolio and pipeline as it manages softer near term demand. For you as an investor, the reset comes after a tough stretch for Zoetis shares, with the stock at $122.41 and showing a 27.9% decline over the past year...

Read More